GLA
Alpha-galactosidase A
Also known as: AGAL_HUMAN, GALA
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P06280
- Gene
- GLA
- Ensembl
- ENSG00000102393
- Chromosome
- X
- Canonical length
- 429 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Secretome location
- Intracellular and membrane
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. This enzyme predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. A variety of mutations in this gene affect the synthesis, processing, and stability of this enzyme, which causes Fabry disease, a rare lysosomal storage disorder that results from a failure to catabolize alpha-D-galactosyl glycolipid moieties. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
429 residues, UniProt reviewed canonical sequence.
>P06280|GLA
1 MQLRNPELHL GCALALRFLA LVSWDIPGAR ALDNGLARTP TMGWLHWERF MCNLDCQEEP
61 DSCISEKLFM EMAELMVSEG WKDAGYEYLC IDDCWMAPQR DSEGRLQADP QRFPHGIRQL
121 ANYVHSKGLK LGIYADVGNK TCAGFPGSFG YYDIDAQTFA DWGVDLLKFD GCYCDSLENL
181 ADGYKHMSLA LNRTGRSIVY SCEWPLYMWP FQKPNYTEIR QYCNHWRNFA DIDDSWKSIK
241 SILDWTSFNQ ERIVDVAGPG GWNDPDMLVI GNFGLSWNQQ VTQMALWAIM AAPLFMSNDL
301 RHISPQAKAL LQDKDVIAIN QDPLGKQGYQ LRQGDNFEVW ERPLSGLAWA VAMINRQEIG
361 GPRSYTIAVA SLGKGVACNP ACFITQLLPV KRKLGFYEWT SRLRSHINPT GTVLLQLENT
421 MQMSLKDLLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GLA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 37 nTPM
Expression across tissuesHPA
Tissue
- seminal vesicle: 37 nTPM
- parathyroid gland: 30 nTPM
- breast: 25 nTPM
- bone marrow: 24 nTPM
- duodenum: 21 nTPM
- placenta: 21 nTPM
Single-cell type
- platelets: 427 nCPM
- cdc: 332 nCPM
- plasma cells: 265 nCPM
- syncytiotrophoblasts: 210 nCPM
- neutrophils: 207 nCPM
- macrophages: 179 nCPM
Immune cell
- non-classical monocyte: 41 nTPM
- intermediate monocyte: 39 nTPM
- classical monocyte: 37 nTPM
- myeloid DC: 30 nTPM
- basophil: 23 nTPM
- neutrophil: 22 nTPM
Brain region
- white matter: 9 nTPM
- pons: 6.8 nTPM
- midbrain: 6.7 nTPM
- medulla oblongata: 6 nTPM
- thalamus: 6 nTPM
- cerebellum: 5.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about GLA.
Disease | AllUniProt
Conditions GLA is implicated in, by any mechanism.
- Fabry disease (FD) MIM:301500
Disease | GeneticClinVar
1,124 pathogenic / likely-pathogenic of 2,028 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Fabry disease
- Cardiovascular phenotype
- Migalastat response
- GLA-related disorder
- Nonpapillary renal cell carcinoma
Disease | ImmuneIEDB
Conditions an epitope on GLA was assayed in.
- colonic benign neoplasm T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.18
- gnomAD pLI
- 1
- gnomAD missense Z
- 1.88
- DepMap mean gene effect
- -0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- glycoside catabolic process
- glycosphingolipid catabolic process
- glycosylceramide catabolic process
- negative regulation of nitric oxide biosynthetic process
- negative regulation of nitric-oxide synthase activity
- oligosaccharide metabolic process
Molecular functions
- alpha-galactosidase activity
- catalytic activity
- hydrolase activity
- protein homodimerization activity
- signaling receptor binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of GLA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GLA as an antibody target. Whether an autoantibody or antibody against GLA could matter depends on whether native GLA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GLA is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label GLA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...